Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

This study tests whether stem cells derived from human amniotic tissue (material from the placenta) can treat calciphylaxis — a rare and extremely painful condition where calcium deposits form inside small blood vessels, causing severe skin wounds and ulcers that are very difficult to heal. It mainly affects people with chronic kidney disease or those on dialysis, and current treatments are limited. **You may be eligible if...** - You are between 18 and 75 years old - You have been clinically diagnosed with calciphylaxis - You have chronic kidney disease, whether or not you are on dialysis (hemodialysis or peritoneal dialysis) - You have signed informed consent **You may NOT be eligible if...** - You have an active cancer or severe psychiatric disorder - Your expected survival is less than 6 months - You are pregnant or breastfeeding - You participated in another experimental drug trial within the last 90 days Talk to your doctor to see if this trial is right for you.